An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®

Inclusion Criteria: 1. Adult patients (age ≥18 years) who are diagnosed with CP-CML, AP-CML, BP-CML, or Ph+ ALL 2. Patients who are initiating Iclusig therapy for the first time, or for whom Iclusig therapy was initiated within 30 days before registry enrollment. 3. The decision to prescribe Iclusig must have been made prior to enrollment in the registry and based upon approved US indications. 4. Patients who have the ability to understand the requirements of the registry, and provide written informed consent to comply with the registry data collection procedures. Exclusion Criteria: 1. Patients previously treated with investigational Iclusig. 2. Patients receiving any investigational agent (eg, any drug or biologic agent or medicaldevice that has not received approval in the US) or receiving Iclusig for any indication not currently approved in the US. 3. Concurrent treatment with another TKI.